NO301520B1 - Fremgangsmåte for fremstilling av et system for regulert frigjöring av aktive stoffer - Google Patents
Fremgangsmåte for fremstilling av et system for regulert frigjöring av aktive stoffer Download PDFInfo
- Publication number
- NO301520B1 NO301520B1 NO900428A NO900428A NO301520B1 NO 301520 B1 NO301520 B1 NO 301520B1 NO 900428 A NO900428 A NO 900428A NO 900428 A NO900428 A NO 900428A NO 301520 B1 NO301520 B1 NO 301520B1
- Authority
- NO
- Norway
- Prior art keywords
- release
- active
- active agent
- pharmaceutical
- excipient
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000008569 process Effects 0.000 title claims abstract description 11
- 238000013270 controlled release Methods 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000004014 plasticizer Substances 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000002357 osmotic agent Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 239000003630 growth substance Substances 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 230000002706 hydrostatic effect Effects 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims 1
- 235000019801 trisodium phosphate Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 25
- 239000012528 membrane Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000036765 blood level Effects 0.000 abstract description 2
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000011162 core material Substances 0.000 description 18
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 16
- 229960004166 diltiazem Drugs 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 12
- 230000003204 osmotic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229930010796 primary metabolite Natural products 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NZHUXMZTSSZXSB-MOPGFXCFSA-N Deacetyldiltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 NZHUXMZTSSZXSB-MOPGFXCFSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- -1 compound potassium chloride Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Filling Or Discharging Of Gas Storage Vessels (AREA)
- Operation Control Of Excavators (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD89325354A DD295760A5 (de) | 1989-01-31 | 1989-01-31 | Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung |
| DE19893932987 DE3932987A1 (de) | 1989-10-03 | 1989-10-03 | System fuer die kontrollierte freisetzung von wirkstoffen und verfahren zu seiner herstellung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO900428D0 NO900428D0 (no) | 1990-01-30 |
| NO900428L NO900428L (no) | 1990-08-01 |
| NO301520B1 true NO301520B1 (no) | 1997-11-10 |
Family
ID=25748261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO900428A NO301520B1 (no) | 1989-01-31 | 1990-01-30 | Fremgangsmåte for fremstilling av et system for regulert frigjöring av aktive stoffer |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0381181B1 (es) |
| JP (1) | JP2885858B2 (es) |
| AT (1) | ATE126052T1 (es) |
| AU (1) | AU641136B2 (es) |
| CA (1) | CA2009045A1 (es) |
| DE (1) | DE69021405T2 (es) |
| DK (1) | DK0381181T3 (es) |
| ES (1) | ES2078251T3 (es) |
| FI (1) | FI900470A0 (es) |
| GR (1) | GR3017861T3 (es) |
| HU (1) | HU205851B (es) |
| IE (1) | IE69174B1 (es) |
| NO (1) | NO301520B1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ238867A (en) * | 1990-07-12 | 1993-08-26 | Alza Corp | Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| WO1996019974A1 (fr) * | 1994-12-27 | 1996-07-04 | Kanebo, Ltd. | Preparation a liberation prolongee |
| US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
| US6074669A (en) * | 1997-01-20 | 2000-06-13 | Ranbaxy Laboratories Limited | Controlled drug delivery system for diltiazem |
| JP4848101B2 (ja) * | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | 徐放性マイクロペレット |
| RU2322233C2 (ru) * | 2002-03-11 | 2008-04-20 | Алькон, Инк. | Имплантируемая система для доставки лекарственных средств |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| GB2150434B (en) * | 1983-12-01 | 1987-11-04 | Alza Corp | Constant rate release systems |
| US4753802A (en) * | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
| EP0250374B1 (en) * | 1986-06-17 | 1991-05-02 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Therapeutic system for controlled release of drugs |
| US4801461A (en) * | 1987-01-28 | 1989-01-31 | Alza Corporation | Pseudoephedrine dosage form |
-
1990
- 1990-01-30 FI FI900470A patent/FI900470A0/fi not_active IP Right Cessation
- 1990-01-30 JP JP2021910A patent/JP2885858B2/ja not_active Expired - Lifetime
- 1990-01-30 HU HU90591A patent/HU205851B/hu not_active IP Right Cessation
- 1990-01-30 NO NO900428A patent/NO301520B1/no unknown
- 1990-01-30 IE IE33690A patent/IE69174B1/en not_active IP Right Cessation
- 1990-01-31 AT AT90101888T patent/ATE126052T1/de not_active IP Right Cessation
- 1990-01-31 DK DK90101888.7T patent/DK0381181T3/da active
- 1990-01-31 AU AU48988/90A patent/AU641136B2/en not_active Ceased
- 1990-01-31 EP EP90101888A patent/EP0381181B1/en not_active Expired - Lifetime
- 1990-01-31 ES ES90101888T patent/ES2078251T3/es not_active Expired - Lifetime
- 1990-01-31 CA CA002009045A patent/CA2009045A1/en not_active Abandoned
- 1990-01-31 DE DE69021405T patent/DE69021405T2/de not_active Expired - Fee Related
-
1995
- 1995-10-25 GR GR950402965T patent/GR3017861T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69021405D1 (de) | 1995-09-14 |
| DK0381181T3 (da) | 1995-10-30 |
| CA2009045A1 (en) | 1990-07-31 |
| EP0381181B1 (en) | 1995-08-09 |
| FI900470A0 (fi) | 1990-01-30 |
| IE900336L (en) | 1990-07-31 |
| JP2885858B2 (ja) | 1999-04-26 |
| AU4898890A (en) | 1990-08-09 |
| EP0381181A3 (en) | 1991-09-18 |
| EP0381181A2 (en) | 1990-08-08 |
| HU900591D0 (en) | 1990-04-28 |
| JPH02282324A (ja) | 1990-11-19 |
| ES2078251T3 (es) | 1995-12-16 |
| IE69174B1 (en) | 1996-08-07 |
| AU641136B2 (en) | 1993-09-16 |
| NO900428L (no) | 1990-08-01 |
| DE69021405T2 (de) | 1996-04-11 |
| GR3017861T3 (en) | 1996-01-31 |
| NO900428D0 (no) | 1990-01-30 |
| HUT53284A (en) | 1990-10-28 |
| ATE126052T1 (de) | 1995-08-15 |
| HU205851B (en) | 1992-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2085078B1 (en) | Controlled porosity osmotic pump tablet of high permeable drugs and the preparation method thereof | |
| IE61223B1 (en) | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties | |
| RU2073998C1 (ru) | Способ получения состава для регулированного выделения активных соединений | |
| NO20130984L (no) | Forlenget frigjøring - farmasøytisk tablett av metformin | |
| US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
| NO311403B1 (no) | Leveringsinnretning med innkapslede eksipienser og fremgangsmåte for avgivelse av et middel | |
| NO301520B1 (no) | Fremgangsmåte for fremstilling av et system for regulert frigjöring av aktive stoffer | |
| WO2021223480A1 (zh) | 一种替格瑞洛控释片及其制备方法 | |
| US20220401446A1 (en) | Controlled release tofacitinib compositions | |
| EP1951210B1 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
| US20090297602A1 (en) | Modified Release Loxoprofen Compositions | |
| JPH04360826A (ja) | 放出制御製剤 | |
| JP2567427B2 (ja) | 浸透分配経口投与製剤 | |
| US20070087056A1 (en) | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility | |
| CN112691086A (zh) | 微孔型琥珀酸美托洛尔缓释片及其制备方法 | |
| Theeuwes et al. | Drug delivery and therapeutic systems | |
| KR102589344B1 (ko) | 산 민감성 성분을 포함하는 삼투성 제제 조성물 | |
| EP3331505B1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof | |
| Kokane Prajakta et al. | INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES | |
| WO2013168177A2 (en) | Osmotically controlled drug delivery systems | |
| WO2014014427A1 (en) | Modified release pharmaceutical tablet formulations |